Hemlibra was found to ease pain and improve quality of life for hemophilia A patients, even those with long-term joint damage ...

NHS England has agreed to reimburse Roche’s Hemlibra (emicizumab) in a new group of patients with haemophilia A, widening access to the potentially life-saving drug. Following the commissioning ...

While Roche is still involved in cancer drugs, it is diversifying into other disease areas and has targeted the haemophilia market with Hemlibra (emicizumab). With this new indication, Hemlibra is ...

Emicizumab (Hemlibra) was approved by the FDA in 2018 to prevent and reduce bleeding for patients who suffer from hemophilia A. The HAVEN 7 trial showed that emicizumab is both safe and effective ...